Quest Partners LLC Acquires Shares of 2,255 Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Quest Partners LLC acquired a new position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 2,255 shares of the company’s stock, valued at approximately $61,000.

Other large investors also recently made changes to their positions in the company. Janney Montgomery Scott LLC raised its holdings in shares of Tarsus Pharmaceuticals by 11.5% in the fourth quarter. Janney Montgomery Scott LLC now owns 24,227 shares of the company’s stock valued at $491,000 after buying an additional 2,500 shares during the last quarter. Trexquant Investment LP bought a new position in shares of Tarsus Pharmaceuticals in the fourth quarter worth about $800,000. RTW Investments LP lifted its position in shares of Tarsus Pharmaceuticals by 9.4% during the fourth quarter. RTW Investments LP now owns 3,152,341 shares of the company’s stock worth $63,835,000 after purchasing an additional 271,640 shares in the last quarter. TFG Asset Management GP Ltd lifted its position in shares of Tarsus Pharmaceuticals by 30.1% during the fourth quarter. TFG Asset Management GP Ltd now owns 800,000 shares of the company’s stock worth $16,200,000 after purchasing an additional 185,000 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC grew its stake in shares of Tarsus Pharmaceuticals by 2.6% during the first quarter. Allspring Global Investments Holdings LLC now owns 192,303 shares of the company’s stock valued at $6,990,000 after purchasing an additional 4,889 shares during the last quarter. Institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Trading Up 4.8 %

Shares of NASDAQ TARS opened at $32.55 on Thursday. Tarsus Pharmaceuticals, Inc. has a fifty-two week low of $12.57 and a fifty-two week high of $42.50. The firm has a market capitalization of $1.23 billion, a P/E ratio of -6.82 and a beta of 1.06. The company has a debt-to-equity ratio of 0.28, a current ratio of 7.03 and a quick ratio of 6.99. The company’s 50 day simple moving average is $27.25 and its 200 day simple moving average is $31.04.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.88) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.98) by $0.10. Tarsus Pharmaceuticals had a negative return on equity of 63.99% and a negative net margin of 180.00%. The company had revenue of $40.81 million for the quarter, compared to the consensus estimate of $31.30 million. During the same quarter in the prior year, the business posted ($1.17) EPS. On average, analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.68 EPS for the current year.

Analyst Ratings Changes

Several research firms recently weighed in on TARS. Oppenheimer restated an “outperform” rating and issued a $63.00 price objective (up previously from $61.00) on shares of Tarsus Pharmaceuticals in a research report on Friday, August 9th. William Blair upgraded Tarsus Pharmaceuticals to a “strong-buy” rating in a research report on Friday, August 30th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Tarsus Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $51.60.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.